First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Amgen
Amgen
Debiopharm International SA
Boehringer Ingelheim
Memorial Sloan Kettering Cancer Center
Jonsson Comprehensive Cancer Center
City of Hope Medical Center
Medical College of Wisconsin
City of Hope Medical Center
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
Servier